GeoVax Labs (GOVX.OB) Releases Positive Early Trial Results for HIV Vaccine
GeoVax yesterday announced positive news of its ongoing phase IIa clinical trial being designated by the HIV Vaccine Trials Network (HVTN), which is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. Early trial results demonstrate an “excellent” safety profile and highly reproducible immunogenicity regarding the company’s two recombinant DNA-vectored vaccine inoculations. The still-blinded data involved 180 trial participants; participants were enrolled and administered a ratio of two vaccine recipients for each placebo; the study so far reveals no safety concerns. These results are very similar to those observed in…